A Comprehensive Cervical Cancer Profile in Nairobi County in Between 2015 and 2019
DOI:
https://doi.org/10.14738/aivp.126.17974Keywords:
Cervical cancer, human papilloma virus, HPV vaccine, awareness, sexual behaviorAbstract
Cervical cancer is the most prevalent cause of cancer-related deaths and morbidity worldwide that is the most common in women aged 45-60, with a disproportional burden in low- and middle-income countries compared to high-income countries. The high illness burden in resource-limited settings is attributed to insufficient knowledge of disease prevention and the lack of organized screening programs. Low middle income countries account for 80% of cervical cancer cases globally. Cervical cancer has a global incidence rate of 14 per 100,000 women. The present study delves to determine the Prevalence of cervical cancer in Nairobi county, to examine the age standard rates of cervical cancer and to determine the survival rates of cervical cancer patients. The study utilized retrospective design where patient records were reviewed to obtain data of Nairobi county women residents who sought medical attention from health care facilities due cervical cancer between the period of 2015-2019. Structured questionnaire obtained from the Nairobi county Abstract form at cancer registry (KEMRI).The data was analyzed using SPSS version 25 and can Reg 5. Descriptive statistics were utilized .The Results revealed that the mean affected age is 49.53 years. Most patients were diagnosed at stage 11 at 19.61%.Radiotherapy was the most preferred form of treatment at 46.75%.The survival rate was at 80.52%..Cervical cancer is considered the most common cancer in women. It is recommended that creating awareness can alter the trajectory of the cervical cancer orientation; training practitioners on high index cancer detection, early screening and adjustments on government policies can increase the survival rate. Moreover, HPV vaccination can prevent growth of malignant cervical cancer cells.
References
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., . . . Estève, J. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 391(10125),
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191-e203.
Awich, L. (2019). Cancer prevalence rate per county. The Star.
Ba, D. M., Ssentongo, P., Musa, J., Agbese, E., Diakite, B., Traore, C. B., Maiga, M. (2021). Prevalence and determinants of cervical cancer screening in five sub-Saharan African countries: a population-based study. Cancer epidemiology, 72, 101930.
Das, M. (2021). WHO launches strategy to accelerate elimination of cervical cancer. The Lancet Oncology, 22(1), Eastment, M. C., Wanje, G., Richardson, B. A., Mwaringa, E., Patta, S., Sherr, K., McClelland, R. S. (2022). A crosssectional study of the prevalence, barriers, and facilitators of cervical cancer screening in family planning clinics in Mombasa County, Kenya. BMC Health Services Research, 22(1), 1-8.
Eiras, M., Escoval, A., Grillo, I. M., & Silva-Fortes, C. (2014). The hospital survey on patient safety culture in Portuguese hospitals: instrument validity and reliability. International Journal of Health Care Quality Assurance.
Kanyina, E. W., Kamau, L., & Muturi, M. (2017). Cervical precancerous changes and selected cervical microbial infections, Kiambu County, Kenya, 2014: a cross sectional study. BMC infectious diseases, 17, 1-5.
Lemp, J. M., De Neve, J.-W., Bussmann, H., Chen, S., Manne-Goehler, J., Theilmann, M., Tsabedze-Sibanyoni, L. (2020). Lifetime prevalence of cervical cancer screening in 55 low-and middle-income countries. Jama, 324(15),
Mchome, B., Swai, P., Wu, C., Katanga, J., Kahesa, C., Manongi, R., Linde, D. S. (2020). Comprehensive cervical cancer prevention in Tanzania (CONCEPT) study: cohort profile. BMJ open, 10(9), e038531.
Musa, J., Nankat, J., Achenbach, C. J., Shambe, I. H., Taiwo, B. O., Mandong, B., . . . Sagay, A. S. (2016). Cervical cancer survival in a resource-limited setting-North Central Nigeria. Infectious agents and cancer, 11(1), 1-7.
Mwaliko, E., Itsura, P., Keter, A., De Bacquer, D., Buziba, N., Bastiaens, H., . . . Gichangi, P. (2023). Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya. BMC cancer, 23(1), 1104.
Serrano, B., Brotons, M., Bosch, F. X., & Bruni, L. (2018). Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology, 47, 14-26.
Singh, D., Vignat, J., Lorenzoni, V., Eslahi, M., Ginsburg, O., Lauby-Secretan, B., . . . Vaccarella, S. (2023). Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health, 11(2), e197-e206.
Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A. (2017). Global cancer in women: burden and trends. Cancer epidemiology, biomarkers & prevention, 26(4), 444-457.
WHO. (2018). Improving data for decision-making: a toolkit for cervical cancer prevention and control programmes.
WHO. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: web annex A: syntheses of evidence.
Zhang, X., Zeng, Q., Cai, W., & Ruan, W. (2021). Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC public health, 21(1), 1-10.
Zhao, M., Wu, Q., Hao, Y., Hu, J., Gao, Y., Zhou, S., & Han, L. (2021). Global, regional, and national burden of cervical cancer for 195 countries and territories, 2007–2017: findings from the Global Burden of Disease Study 2017. BMC Women's Health, 21(1), 1-13.
Aniekwu NI. Gender and human rights dimensions of HIV/AIDS in Nigeria. African Journal of Reproductive Health. 2002;6(3):30- 37.
Brinton LA, Schairer C, Haenszel W. Cigarette smoking and invasive cervical cancer [Article]. J Am Med Assoc. 1986;255(23):3265–3269.
Ahmed, M. A. . Cancer Prevalence in Wajir County, Kenya: Estimation Using Cancer Data at the Healthcare Facilities. Journal of Medicine, Nursing &Public Health, (2021) 4(1), 25-45.
Araghi, M., Soerjomataram, I., Jenkins, M., Brierley, J., Morris, E., Bray, F., & Arnold, M. (2019). Global trends in colorectal cancer mortality: projections to the year 2035. International journal of cancer, 144(12), 2992-3000.
Arbyn, M.; Weiderpass, E.; Bruni, L.; de Sanjosé, S.; Saraiya, M.; Ferlay, J.; Bray, F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health 2020, 8, e191–e203.
Cibula, D.; Pötter, R.; Planchamp, F.; Avall-Lundqvist, E.; Fischerova, D.; Haie-Meder, C.; Köhler, C.; Landoni, F.; Lax, S.; Lindegaard, J.C.; et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Arch. 2018, 472, 919–936. de Sanjose, S.; Brotons, M.; Pavon, M.A. The natural history of human papillomavirus infection. Best Pract. Res.
Clin. Obstet. Gynaecol. 2018, 47, 2–13. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11:1048-1056.
Edelman, C.L. &Mandle C.L. (2006), Health Promotion throughout the lifespan (5th Edition). St. Louis Missouri: Elsevier Mosby Einstein MH, Schiller JT, Viscidi RP, et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009; 9:347-356.
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Population Fact Sheets: Africa. Lyon, France: International Agency for Research on Cancer, 2018. https://gco.iarc.fr/today/data/factsheets/populations/903-africa-fact-sheets.pdf.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide. Lyon: International Agency for Research on Cancer; 2013. (IARC CancerBase No. 11).
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., ... & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer, 144(8), 1941-1953
Green J. Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20–44 years: the UK National case–control study of cervical cancer. Br J Cancer. 2003 [2003 December 01];89(11):2078–2086.
Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89:465-491. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervic ovaginal papillomavirus infection in young women [Article]. New Engl J Med. 1998;338(7):423–428.
Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. ClinInfect Dis. 2013; 57:735-744.
Kelly H, Weiss HA, Benavente Y, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and metaanalysis. Lancet HIV. 2018;5:e45-e58.
Kenya National Cancer Organizations, (2014), Kenya Cancer Statistics & National Strategies Retrieved from: https://kenyacancernetwork.wordpress.com/kenya-cancer-facts/
Korir, A., Okerosi, N., Ronoh, V., Mutuma, G., & Parkin, M. (2015). Incidence of cancer in N airobi, K enya (2004–2008). International journal of cancer, 137(9), 2053-2059.
Khaemba, E. N., Mugo, C. W., & Mutai, C. (2013). The Survival Of Patients With Cancer Of The Cervix In Nairobi, Kenya.
Macharia, L. W., Mureithi, M. W., & Anzala, O. (2018). Cancer in Kenya: types and infection attributable. Data from the adult population of two National referral hospitals (2008- 2012). AAS Open Research, 1. Makama GA. Patriarchy and Gender Inequality in Nigeria: The Way Forward. European Scientific Journal. 2013;9(17):1857- 7881.
Makau-Barasa, L. K., Greene, S. B., Othieno-Abinya, N. A., Wheeler, S., Skinner, A., & Bennett, A. V. (2017). Improving access to cancer testing and treatment in Kenya. Journal of Global Oncology, 4, 1-8.
Maranga, I. O., Hampson, L., Oliver, A. W., Gamal, A., Gichangi, P., Opiyo, A. ... & Hampson, I. N. (2013). Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya. PloS one, 8(10), e78411.
Massad LS, Xie X, D’Souza G, et al. Incidence of cervical precancers among HIV-seropositive women. Am J Obstet Gynecol. 2015;212:606.e1-e8.
McHome B, Linde DS, Manongi R, et al. Incident detection of human papillomavirus—a prospective follow-up study among Tanzanian women with focus on HIV status. Int J Infect Dis. 2021; 110:165-170.
McLeroy, K. R., Bibeau, D., Steckler, A., & Glanz, K. (1988). An ecological perspective on health promotion programs. Health education quarterly, 15(4), 351-377.
Ministry of Health: National Cancer Control Strategy 2017 – 2022. 2017.
Morandell, D.; Rostek, U.; Bouvard, V.; Campo-Fernandez, B.; Fiedler, M.; Jansen-Durr, P.; Zwerschke, W. Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. Virology 2008, 379, 20–29.
Parkin DM, Sitas FD, Chirenje M, Stein L, Abratt R, and Wabinga H (2008). Part I: Cancer in Indigenous Africans—burden, distribution, and trends. Lancet Oncology Vol 9: 683–692
Parkin DM, Bray F, Ferlay J, et al.: Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev. 2014; 23(6): 953–966. PubMed Abstract | Publisher Full Text Plummer M, de Martel C, Vignat J, et al.: Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY-NC-ND license; 2016; 4(9): e609–e616. Possati-Resende, J.C.; Fregnani, J.H.; Kerr, L.M.; Mauad, E.C.; Longatto-Filho, A.; Scapulatempo-Neto, C. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS ONE 2015, 10, e0134445. [CrossRef] [PubMed]
Ruto, P. K., Muitta, E., Owino, A., & Makokha, F. W. (2020). Frequency and Pattern of All Cancer Cases at Thika Level Five Hospital in Kiambu County, Kenya. International Research Journal of Oncology, 1-9. Ortiz AP, Engels EA, Nogueras-Gonzalez GM, et al. Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected Hispanics living in the United States. Cancer. 2018;124:4520-4528.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
Silverberg MJ, Leyden WA, Chi A, et al. Human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol. 2018;131:47-55.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Samantha, L. & Lawrence N., (2019), Cancer as a Non-Communicable Disease and the Status of Cancer Control in Kenya, KIPPRA; Retrieved from: https://kippra.or.ke/cancer-as-a-non communicable-disease-and-the-status-ofcancer-control-in-kenya/Salambanga, C.; Zohoncon, T.M.; Traore, I.M.A.; Ouedraogo, R.A.; Djigma, W.F.; Ouedraog, C.; Simpore, J. High prevalence of high-risk human papillomavirus (HPV) infection among sexually active women in Ouagadougou.
Med. Sante Trop. 2019, 29, 302–305.
Stolnicu, S.; Barsan, I.; Hoang, L.; Patel, P.; Terinte, C.; Pesci, A.; Aviel-Ronen, S.; Kiyokawa, T.; Alvarado-Cabrero, I.; Pike, M.C. International Endocervical Adenocarcinoma Criteria and Classifification (IECC): A new pathogenetic classifification for invasive adenocarcinomas of the endocervix. Am. J. Surg. Pathol. 2018, 42, 214.
Sankaranarayanan R, Ramadas K, Thara S et al. (2011). Clinical breast examination: preliminary results from a randomized controlled trial in India. Journal of the National Cancer Institute, 103:1476-1480
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [Article]. CA Cancer J Clin. 2015;65(2):87–108.
Uwins, C.; Patel, H.; Bhandoria, G.P.; Butler-Manuel, S.; Tailor, A.; Ellis, P.; Chatterjee, J. Laparoscopic and robotic surgery for endometrial and cervical cancer. Clin. Oncol. 2021, 33, e372–e382.
Szarewski, A.; Ambroisine, L.; Cadman, L.; Austin, J.; Ho, L.; Terry, G.; Liddle, S.; Dina, R.; McCarthy, J.; Buckley, H. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Prev. Biomark. 2008, 17, 3033–3042. [CrossRef]
Van Eerd EAM, Bech Risør M, Spigt M, et al. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. NPJ Prim Care Respir Med. 2017 [2017 June 23];27(1):41.
Wambalaba, F. W., Son, B., Wambalaba, A. E., Nyong’o, D., & Nyong’o, A. (2019). Prevalence and Capacity of Cancer Diagnostics and Treatment: A Demand and Supply Survey of Health-Care Facilities in Kenya. Cancer Control, 26(1), 1073274819886930.
Wambalaba, F. W., Son, B., Wambalaba, A. E., Nyong’o, D., & Nyong’o, A. (2019). Prevalence and Capacity of Cancer Diagnostics and Treatment: A Demand and Supply Survey of Health-Care Facilities in Kenya. Cancer Control, 26(1), 1073274819886930
Whitworth HS, Gallagher KE, Howard N, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine. 2020; 38:1302-1314.
World Health Organization (WHO), & International Agency for Research on Cancer. (2020). Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Geneva; 2018.
World Health Organization. (2018). Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer. Geneva: World Health Organization.
Wright, T.C., Jr.; Behrens, C.M.; Ranger-Moore, J.; Rehm, S.; Sharma, A.; Stoler, M.H.; Ridder, R. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol. Oncol. 2017, 144, 51–56. [CrossRef]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anne Chepkemboi Langat, Evans Tanui
This work is licensed under a Creative Commons Attribution 4.0 International License.
